Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Piper Sandler

Teens Spending More On Shopping, But Concerned About Russia-Ukraine War, Reveals Piper Report

According to Piper Sandler’s biannual “Taking Stock With Teens” report, teenagers are spending more and shifting their shopping habits, even as they worry about growing economic uncertainty,

Benzinga

10 Biggest Price Target Changes For Wednesday

Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.

Benzinga

10 Biggest Price Target Changes For Tuesday

Piper Sandler cut the price target on The Goldman Sachs Group, Inc. (NYSE: GS) from $465 to $430. Goldman Sachs shares rose 0.1% to $328.60 in pre-market trading.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Tesla Analysts Are Shrugging Off Q1 Deliveries Miss, Remain Bullish On The EV Stock

Tesla, Inc. (NASDAQ: TSLA) reported first-quarter delivery numbers over the weekend that narrowly missed the consensus expectation.

Benzinga

Piper Sandler Sees 21% Upside In This Cloud Computing Platform

Piper Sandler analyst James Fish initiated coverage of DigitalOcean Holdings Inc (NYSE:DOCN) with an Overweight rating and a $72 price target (21% upside). Fish expects DigitalOcean to benefit from the shift of the 18% public cloud workload annual growth in which cloud spending is only 23% of broader infrastructure spending today. The analyst notes…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

Upgrades

Benzinga

Read How Analysts Reacted To Blend Labs' Q4 Results

Analysts mainly slashed the price targets or downgraded the rating on Blend Labs Inc (NYSE:BLND) post Q4 results. KeyBanc analyst Josh Beck lowered the price target to $6 from $10 (26% upside) and kept an Overweight. The company's FY22 revenue forecast was well below the Street's $343.8 million, reflecting the negative impact of higher rates…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Upgrades

Benzinga

Analysts Agree: Federal Cannabis Legalization Unlikely To Happen Soon, Does SAFE Act Have Better Chance This Year?

Federal cannabis legalization is unlikely to happen any time soon, according to analysts from Piper Sandler and Beacon Policy Advisors LLC.

Benzinga

Mosaic Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Mosaic (NYSE:MOS). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

10 Biggest Price Target Changes For Monday

Keybanc cut the price target on Global Payments Inc. (NYSE: GPN) from $175 to $165. Global Payments shares rose 0.4% to $136.72 in pre-market trading.

Benzinga

Why Beyond Meat Stock Is Sliding Today

Beyond Meat Inc (NASDAQ: BYND) is trading lower Monday morning following bearish analyst coverage from Piper Sandler.

Benzinga

Read How Analysts Reacted To This Wood Pellet Grill Maker's Q4 Results

Morgan Stanley analyst John Glass lowered the price target on Traeger Inc (NYSE:COOK) to $10 from $26 and maintained an Equal Weight rating on the shares. The revised price target implies a 31.23% upside. Glass noted grill demand appears to be softening post-COVID to a greater extent than previously expected. Traeger's shares are…

Benzinga

10 Biggest Price Target Changes For Thursday

Piper Sandler cut the price target on Wingstop Inc. (NASDAQ: WING) from $195 to $102. Wingstop shares fell 0.7% to trade at $111.44 on Thursday.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

Benzinga

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged. Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. Wall Street's estimate for sales…

Benzinga

China's Lockdown Of Tech Hubs To Hamper Amazon, Walmart's Online Delivery: Report

China's recent lockdown looks to hamper the online order delivery of global e-commerce firms like Amazon.com Inc (NASDAQ:AMZN) and Walmart Inc (NYSE:WMT), Bloomberg reports. China had to initiate lockdowns and restrictions in its crucial manufacturing hubs like Shenzhen and Dongguan following a Covid-19 resurgence. Related Content: China Restricts Activities In Shenzhen, Shanghai Following Covid-19 Resurgence The…

Benzinga

KeyBanc Remains Upbeat On Apple Citing iPhone SE 3; BofA, Piper Sandler See Limited Impact From China Lockdown

KeyBanc's Key First Look Data suggested that Apple Inc (NASDAQ: AAPL) tracked slightly better than historical seasonality. The indexed spending was down (9)% month-on-month in February, beating the 3-year average decline of (13)%.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Piper Sandler Cuts Ameresco Price Target By 20%

Ameresco Inc (NYSE:AMRC) price target was lowered to $64 (a downside of 7%) from $80 by Piper Sandler analyst Kashy Harrison. The analyst maintained the Neutral rating on Ameresco shares. Harrison noted that European demand for non-Russian energy supply will "skyrocket." He thinks that the Ukraine crisis boosts demand for renewables/alternatives and is positive for…

Benzinga

Analysts Slash Their PTs On Oracle As They Did Not Buy Its Growth Story

Analysts slashed their price targets on Oracle Corp (NYSE:ORCL) post Q3 results. Piper Sandler analyst Brent Bracelin downgraded to Underweight from Neutral with a PT of $70 (8.7% downside), down from $100. Bracelin found it challenging to reach double-digit organic growth next year, sustaining a cloud shift considering more than 70% of revenue came from the…

Benzinga

Piper Sandler Remains Cautious On Tesla Despite Noting Its Strength

Piper Sandler analyst Alexander Potter admitted that the current weekly China Passenger Car Association February sales and production exhibited continued strength for Tesla Inc's (NASDAQ:TSLA) Shanghai factory. Tesla sold 56,515 China-made vehicles in February, including 33,315 for export. Potter also noticed a "general uptick in inbound calls" from investors regarding Tesla's exposure to geopolitical risks and commodity price…

Benzinga

Why Palantir Shares Are Ripping Higher

Palantir Technologies Inc (NYSE: PLTR) is surging Wednesday after Piper Sandler analyst Weston Twigg initiated coverage on the stock with an Overweight rating and a $15 price target.

Benzinga

Analysts Continue To See Sharp Upside In Bumble Post Q4

Analysts continue to see sharp upside in Bumble Inc (NASDAQ:BMBL) despite cutting their price targets post Q4 results. BMO Capital analyst Daniel Salmon upgraded to Outperform from Market Perform with an unchanged price target of $48 (103% upside). Online dating is poised to outperform the internet sector. Cowen analyst John Blackledge raised the price target to $38…

Benzinga

Why This Data Analytics Company's 'High Growth' Will Likely Continue

Palantir Technologies Inc. (NYSE: PLTR), while being controversial, has set its sights on achievable growth targets, according to an analyst at Piper Sandler.

Benzinga

Piper Sandler Slashes Facebook Parent Meta's Price Target By 20%; Reiterates Overweight

Piper Sandler cut its price target on the Meta Platforms Inc (NASDAQ: FB), noting that its advertising headwinds are likely to continue for several months. Analyst Thomas Champion lowered his price target to $240 from $301, implying a 28% upside.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations